Pharmacology
All Targets
7-TM Receptors
Ion Channels
Nuclear Receptors
Enzyme-Linked Receptors
Transporters
Enzymes
Other Pharmacology
Cellular Processes
Angiogenesis
Apoptosis
Cell Cycle
Cell Metabolism
Cytoskeleton & Motor Proteins
ECM & Adhesion Molecules
Epigenetics
Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
VUF 10166Cat. No. 4532 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: 2-Chloro-3-(4-methyl-1-piperazinyl)quinoxaline |
Biological Activity
High affinity 5-HT3 receptor antagonist (IC50 values are 0.04 and 22 nM for human 5HT3A and 5-HT3AB receptors respectively). Exhibits partial agonist activity at 5-HT3A receptors at higher concentrations (EC50 = 5.2 μM). Also histamine H4 receptor antagonist (pKi = 6.64 in HEK cells).Certificate of Analysis / Safety Data Sheet
Certificate of Analysis: View current batch
Safety Data Sheet: View Safety Data Sheet
References
Smits et al (2008) Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo. J.Med.Chem. 51 2457. PMID: 18357976.
Thompson et al (2012) VUF10166, a novel compound with differing activities at 5-HT3A and 5-HT3AB receptors. J.Pharmacol.Exp.Ther. 341 350. PMID: 22306960.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: VUF 10166, supplier, 5-ht, serotonin, receptors, antagonists, high, affinity, partial, agonists, 5-ht3a, 5-ht3ab, 5-ht3, 5ht, VUF10166
Quick Order
Find multiple products by catalog number
New Products in this Area
Sign-up for new product e-alerts
Tocris Events
Win a Kindle
5th Conference on Advances in Molecular Mechanisms Underlying Neurological Disorders
June 23 - 26, 2013
Bath, UK



